Back to top
more

Health Catalyst (HCAT)

(Delayed Data from NSDQ)

$1.59 USD

1.59
207,298

0.00 (0.00%)

Updated Aug 28, 2026 03:59 PM ET

After-Market: $1.60 +0.01 (0.63%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 248)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Health Catalyst (HCAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Health Catalyst (HCAT) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of +20.00% and +1.66%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Joint Corp. (JYNT) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

The Joint (JYNT) delivered earnings and revenue surprises of +300.00% and +0.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Health Catalyst (HCAT) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Besides Wall Street's top-and-bottom-line estimates for Health Catalyst (HCAT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates

by Zacks Equity Research

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 0.00% and +2.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of +33.33% and +0.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?

by Indrajit Bandyopadhyay

OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.

Harshit Gupta headshot

VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?

by Harshit Gupta

Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.

Indrajit Bandyopadhyay headshot

Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?

by Indrajit Bandyopadhyay

OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.